Hoth Therapeutics Inc. (NASDAQ: HOTH) stock declines by 8.29% in the current market trading session. Hoth Therapeutics is a clinical-stage biopharmaceutical business focusing on creating next-generation medicines for medical conditions that are currently unmet. Hoth’s pipeline is aimed at raising the standard of living for patients with atopic dermatitis, skin toxicities linked to cancer treatments, chronic wounds, psoriasis, asthma, acne, mast-cell related malignancies, and anaphylaxis, and pneumonia.
What is happening?
HOTH has revealed that they have signed a Sponsored Research Agreement with Washington University in St. Louis in order to assist the further research and development of HT-ALZ which is a new therapy for the treatment of Alzheimer’s disease symptoms.
Carla Yuede, Associate Professor of Psychiatry, and John Cirrito, Associate Professor of Neurology, both of Washington University School of Medicine, will lead the study. The link between synaptic activity and amyloid-beta metabolism in Alzheimer’s disease has been the emphasis of Dr. Cirrito’s study. The formation of toxic oligomers and plaques of Amyloid-beta (Abeta) peptide inside the extracellular space of the brain is thought to be the fundamental cause of Alzheimer’s disease. Dr. Yuede’s study focuses on the elements that influence cognitive function and brain Aß dynamics in Alzheimer’s disease animal models, notably synaptic activity.
Robb Knie, Chief Executive Officer of Hoth Therapeutics stated:
Through HOTH’s collaboration with Dr. John Cirrito, Dr. Carla Yuede, and Washington University, HOTH is excited to broaden their research on Alzheimer’s disease. HOTH is pleased about the potential effect of HT-ALZ on the treatment of Alzheimer’s disease and all those afflicted by it. Their objective continues on delivering unique and innovative therapies through development to meet unfulfilled patient needs and produce shareholder value.